<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122691">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01902472</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-276-0103</org_study_id>
    <nct_id>NCT01902472</nct_id>
  </id_info>
  <brief_title>A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)</brief_title>
  <official_title>A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate HIV-1 RNA and the presence or absence of resistance at baseline and
      following seroconversion, assess the frequency of HIV-1 screening and screening method(s)
      used for evaluation of seroconverters, and collect information regarding whether the
      seroconverter experienced signs and symptoms of acute HIV-1 infection prior to or at the
      time of seroconversion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Seroconversion rate among all subjects exposed to emtricitabine (FTC)/ tenofovir disoproxil fumarate (TDF) (Truvada®) for a PrEP indication</measure>
    <time_frame>Baseline to Year 3</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of seroconverters with resistance mutations</measure>
    <time_frame>Baseline to Year 3</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of seroconverters with signs/symptoms at or before seroconversion</measure>
    <time_frame>Baseline to Year 3</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>FTC/TDF for PrEP</arm_group_label>
    <description>HIV-1 negative adults (any sex/gender, including transgender) who seroconvert while taking FTC/TDF for PrEP</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        One hundred fifty (150) HIV-1 negative adults (any sex/gender, including transgender) and
        ≥ 18 years of age who seroconvert while taking FTC/TDF for PrEP.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant in a FTC/TDF PrEP demonstration project or FTC/TDF for PrEP clinical
             study

          -  HIV-1 negative adults (any sex/gender, including transgender) ≥ 18 years of age at
             time of enrollment in the demonstration project or clinical study.

          -  Evidence of seroconversion while receiving FTC/TDF for PrEP

        Exclusion Criteria:

          -  This is an observational nested study and will monitor all reported seroconversions
             without intervention/exclusion.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Rawlings, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca Guzman</last_name>
    <email>rebecca.guzman@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gilead Sciences, Inc.</name>
      <address>
        <city>Foster City</city>
        <state>California</state>
        <zip>94404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>July 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>Truvada</keyword>
  <keyword>FTC/TDF</keyword>
  <keyword>Pre-exposure prophylaxy</keyword>
  <keyword>PrEP</keyword>
  <keyword>Resistance</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
